Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vicuron Pharmaceuticals
King Of Prussia, Pennsylvania, United Statesvicuron.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vicuron had two late-stage anti-infective drugs under FDA review at the time of its acquisition. Anidulafungin showed superiority over fluconazole for invasive candidiasis in Phase III trials. Dalbavancin demonstrated efficacy against resistant Gram-positive pathogens with once-weekly dosing and positive results in complicated skin/soft tissue infection trials as well as catheter-related bloodstream infection studies.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculePeptidesBiologic
- Industry
- Biotech
02
Partnerships
Collaborations with major pharmaceutical companies for orally administered antibiotics and antifungals prior to acquisition
Beyond the preview
Go deeper on Vicuron Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vicuron Pharmaceuticals.